FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2104967400> ?p ?o ?g. }

• W2104967400 endingPage "198" @default.
• W2104967400 startingPage "191" @default.
• W2104967400 abstract "HomeCirculation: Cardiovascular GeneticsVol. 2, No. 2Genetics of Atherothrombotic and Lacunar Stroke Free AccessResearch ArticlePDF/EPUBAboutView PDFSections ToolsAdd to favoritesDownload citationsTrack citationsPermissionsDownload Articles + Supplements ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toSupplementary MaterialsFree AccessResearch ArticlePDF/EPUBGenetics of Atherothrombotic and Lacunar Stroke Stéphanie Debette, MD, PhD and Sudha Seshadri, MD Stéphanie DebetteStéphanie Debette From the Department of Neurology, Boston University School of Medicine and the Framingham Heart Study, Boston, Mass. Search for more papers by this author and Sudha SeshadriSudha Seshadri From the Department of Neurology, Boston University School of Medicine and the Framingham Heart Study, Boston, Mass. Search for more papers by this author Originally published1 Apr 2009https://doi.org/10.1161/CIRCGENETICS.108.828319Circulation: Cardiovascular Genetics. 2009;2:191–198Identifying new risk factors for ischemic stroke occurrence could help improve prevention strategies and identify new therapeutic targets. Genetic risk factors are particularly interesting, because they can offer a direct clue to the biological pathways involved. Ischemic stroke is a heterogeneous disorder, and this must be considered in the search for genetic susceptibility factors. In Western countries, most ischemic strokes can be attributed to large-artery atherosclerosis (atherothrombotic stroke) and small-artery occlusion (lacunar stroke), the rest being due to cardioembolism, vasculitis, monogenic disorders, undetermined causes, or rare etiologies such as cervical artery dissection. According to the Trial of Org 10172 in Acute Stroke Treatment criteria, an ischemic stroke is classified as atherothrombotic (or due to large-artery atherosclerosis) if it is associated with a >50% stenosis of an appropriate intracranial or extracranial artery1 and as lacunar (typically due to lipohyalinosis and microatheroma) if a brain stem or subcortical infarct of ≤1.5-cm diameter can be demonstrated and large-artery atherosclerosis and cardioembolism can be excluded.1In the present study, we reviewed published data on the genetic risk factors underlying atherothrombotic and lacunar strokes. Our reasons for focusing on these 2 subtypes are that (1) extensive reviews exploring the genetic risk factors for total ischemic stroke already exist,2–4 (2) there is some evidence that genetic susceptibility factors may differ according to stroke subtype, and (3) atherothrombotic and lacunar stroke may have a greater genetic component than cardioembolic stroke.5–7Single-Gene Disorders Causing Atherothrombotic and Lacunar StrokeSeveral monogenic disorders can cause large-artery and small-vessel stroke. Overall, they are responsible for a very small proportion of these strokes, probably <1%,8 and should mainly be considered when stroke occurs at a young age in individuals with little or no exposure to conventional vascular risk factors. The mechanisms by which these monogenic disorders result in stroke are varied.Cerebral Autosomal Dominant Arteriopathy, Subcortical Infarcts, and LeukoencephalopathyCerebral autosomal dominant arteriopathy, subcortical infarcts and leukoencephalopathy is a rare autosomal dominant disease caused by mutations in the Notch3 gene on chromosome 19.9Notch3 encodes a cell-surface receptor involved in vascular smooth muscle cell survival and vascular remodeling. The prevalence of this disorder has been estimated at ≈1 of 24 000, which is probably an underestimation (www.orpha.net). Patients with cerebral autosomal dominant arteriopathy, subcortical infarcts and leukoencephalopathy suffer from recurrent lacunar strokes. The phenotype also includes progressive cognitive impairment, psychiatric disturbances—especially mood disturbances—and migraine with aura, with an onset between the third and sixth decade. The underlying vascular lesion is a nonarteriosclerotic, amyloid-negative angiopathy involving small arteries and capillaries.10 The definitive diagnostic test is the molecular genetic analysis of the Notch3 gene. Skin biopsy can reveal characteristic granular osmiophilic material within the vascular basal lamina on electron microscopic examination.11 So far, only symptomatic treatments are available.Sickle Cell DiseaseSickle cell disease is an autosomal recessive disease, which can be due to either a homozygous state for hemoglobin S (HbS) or to the combined heterozygous state with other hemoglobinopathies, such as hemoglobin C (HbC) or mild β-thalassemia.12 HbS results from a mutation on the hemoglobin-β (HBB) gene on chromosome 11, which is present on 3 African haplotypes and a fourth Arab Indian haplotype.12 The prevalence of the disease at birth varies in affected populations between 0.02% and 3% (www.orpha.net). Stroke affects up to 25% of patients aged 45 years and includes both large-artery and small-vessel ischemic stroke (with a peak incidence in early childhood) and hemorrhagic stroke (mainly in adults).13 Large-artery strokes are due to intimal thickening, fibroblast and smooth muscle cell proliferation, and thrombus formation, mainly in the distal internal carotid artery and the proximal middle and anterior cerebral arteries.10,12 Small-vessel strokes are probably caused by sludging and intravascular sickling in smaller vessels. Other clinical features include vaso-occlusive or painful crisis, retinopathy, chronic leg ulcers, and increased susceptibility to infection.12 Transfusion therapy can reduce the risk of stroke.HomocysteinuriaHomocysteinuria includes several heritable, mainly autosomal recessive, diseases causing elevated plasma concentrations of homocysteine and homocysteinuria. The most frequent cause is a mutation in the cystathionine β-synthase (CBS) gene on chromosome 21. On the basis of data from newborn screening, the rate of occurrence of homocysteinuria is ≈1 of 344 000 (www.orpha.net), but prevalence rates of up to 1 of 20 500 have been described in some European countries.14 Thromboembolism is a key clinical feature affecting large and small arteries, and veins. The chances of suffering a thromboembolic event were estimated at 25% by age 16 and 50% by age 29, more than half of these events being venous and 32% cerebrovascular.15 Other clinical features include ectopia lentis, mental retardation, and osteoporosis. Ischemic stroke in homocysteinuria has been primarily attributed to accelerated atherosclerosis.16 However, some pathological studies suggest that arterial damage in homocysteinuria differs from atherosclerosis, most notably by a lack of lipid deposition.17 Other mechanisms could include endothelium-mediated thrombosis through direct toxicity of homocysteine on the endothelium.17 Isolated cases of cervical artery dissection have also been reported.18 Treatments to lower plasma homocysteine levels and stroke risk include pyridoxine, methionine-restricted diet, folate and vitamin B12 supplementation, and betaine.Fabry DiseaseFabry disease is an X-linked disease caused by a mutation in the galactosidase-α (GLA) gene. Women heterozygous for the mutation can also be symptomatic but are usually less severely affected than men. The incidence of the disease is estimated at 1 of 40 000 (www.orpha.net). In a large survey of young patients with cryptogenic ischemic stroke, 4% carried a mutation in GLA.19 Ischemic stroke can be due to both small- and large-vessel disease, with a predominance in the vertebro-basilar circulation.19 Deposition of globotriaosylceramide in the vascular wall and dolichectasia of the basilar and vertebral arteries have been described,10 but the mechanisms underlying stroke are still poorly understood. Clinical features include acroparesthesiae, angiokeratomas, and hypohidrosis, which often develop in childhood or adolescence, before systemic complications leading to strokes, heart failure, and chronic kidney disease occur. The diagnosis is made by measuring α-galactosidase A activity or by mutation screening, the former being less reliable in women. Enzyme-replacement therapy was recently shown to improve some symptoms, but the effect on stroke prevention remains unclear.20Interestingly, recent studies suggest that polymorphisms in other genes can influence the phenotypic expression of these monogenic diseases. In sickle cell disease, in particular, the risk of stroke was shown to be substantially influenced by a variety of modifier genes.21 However, there is no data on whether these modifier genes differentially affect the risk of specific subtypes of ischemic stroke. One of the suggested modifier genes of stroke risk in sickle cell disease, selectin P (SELP),21 was also studied in relation with sporadic lacunar and atherothrombotic stroke, but no significant association was observed (Supplemental Table XII).Genetics of Sporadic Atherothrombotic and Lacunar StrokeImportance of Genetic Factors in Apparently Sporadic Atherothrombotic and Lacunar StrokeThere is an evidence in the literature, both from twin studies22 and from studies on the family history of stroke5,23,24 that genetic factors substantially contribute to stroke susceptibility. However, the influence of family history on stroke risk remains controversial, with some studies describing no impact of parental history on stroke risk.25 Reasons for these inconsistencies may be (1) difficulty in reliably assessing parental stroke status, (2) late occurrence of stroke (parents with a genetic predisposition to stroke may have died of alternative causes before they developed a stroke), and (3) the heterogeneity of stroke, which only some studies have accounted for. Many studies combined ischemic and hemorrhagic stroke and only a few studies considered ischemic stroke subtypes.25 In 4 hospital-based series where patients with ischemic stroke were compared with healthy controls, family history of stroke was found to be independently associated with an increased risk of large-artery stroke (odds ratio [OR], 1.88 [95% CI, 1.02 to 3.44] to 2.24 [1.49 to 3.36]) and small-vessel stroke (OR, 1.79 [1.13 to 2.84] to 2.76 [1.55 to 4.91]), the association with cardioembolic stroke being much weaker.5–7,26 Other studies could not demonstrate any association,27 or only showed a trend toward an increased frequency of positive family history in persons with a lacunar stroke28 and decreased frequency in cardioembolic stroke,29 but these studies did not include a control population and were probably underpowered.Assuming that a positive family history is a marker of increased genetic risk, this risk is expected to be higher in stroke subtypes that are more strongly associated with a positive family history. Thus, the sample size needed to unravel genetic effects is probably smaller when focusing on these subtypes.6 Moreover, certain genetic factors probably predispose to specific subtypes of ischemic stroke only, and not to ischemic stroke overall.6 Focusing on ischemic stroke subtypes for which a stronger genetic component is suspected may therefore be a key element in elucidating the genetic contribution to ischemic stroke. Genetic variants could act at various levels (eg, by increasing the risk of and susceptibility to “conventional” stroke risk factors such as hypertension or diabetes) by influencing specific mechanisms underlying stroke, such as the occurrence and progression of atherosclerosis or lipohyalinosis, by predisposing to arterial thrombosis, or by modifying tolerance to brain ischemia.3 The underlying genetic model is expected to be multifactorial, involving several genetic polymorphisms that each confer small increases in risk, with ORs almost always below 1.5 and usually ≈1.1 to 1.3.30,31 A number of approaches have been used to determine the underlying genetic variants contributing to sporadic ischemic stroke risk, including (1) candidate gene association studies, (2) genome-wide association studies (GWAS), and (3) linkage studies.Search StrategyReferences for this second part of the review were identified through searches of PubMed from 1966 to July 1, 2008, with the terms: gene [MeSH], polymorphism, genetic [MeSH], haplotypes [MeSH], genetic markers [MeSH], linkage (genetics), mutation [MeSH], genetic predisposition to disease, sequence analysis, DNA [MeSH], genotype [MeSH], alleles [MeSH], brain infarction [MeSH], and stroke [MeSH]. We selected only articles that had specific data on genetic variation underlying “all stroke” and “ischemic stroke,” after perusal of all titles, abstracts, and, where necessary, the complete article. We further narrowed our selection to include only articles with pertinent information on the atherothrombotic and/or lacunar subtypes of ischemic stroke. Details on the selection criteria are provided in a methodologic online supplement.Candidate-Gene Association StudiesCandidate-gene association studies test the association of a disease with genetic variants selected through a priori hypotheses about the underlying pathophysiology; typically, they use a case-control study design. We identified 133 candidate-gene association studies that included data on atherothrombotic and lacunar ischemic stroke subtypes and satisfied our inclusion criteria. Data from all these studies are summarized in the online Appendix as a series of 12 Supplemental Tables. Each table summarizes data related to a single etiopathologic pathway. For each study, we describe the gene and specific polymorphism studied, the ethnic composition and size of the study sample, the stroke subtype classification system used, and the number of atherothrombotic and lacunar stroke events. For studies that found an association, the ORs and 95% confidence intervals were reported.Renin-Angiotensin SystemThe insertion/deletion polymorphism in intron 16 of the angiotensin-converting enzyme (ACE) gene is one of the most frequently studied genetic variations in relation to atherosclerosis and vascular disease. ACE converts angiotensin I to the vasoconstrictor angiotensin II and inactivates the vasodilator bradykinin, thus contributing to the regulation of vascular tone, endothelial function, and smooth muscle cell proliferation. The insertion/deletion polymorphism in the ACE gene was significantly associated with lacunar stroke in 3 independent populations, with an increased risk for D-allele carriers.32–34 However, 9 other studies found no association of this variant with lacunar stroke.35–43 None of the studies found an association of the ACE insertion/deletion variant with atherothrombotic stroke, and other ACE variants were associated neither with atherothrombotic nor with lacunar stroke (supplemental Table I).Inflammatory SystemInflammation is a key process in atherosclerosis and therefore stroke and coronary heart disease. Leukotrienes are potent proinflammatory molecules, which are involved in leukocyte recruitment and adhesion to the vascular endothelium, as well as in endothelial cell permeability and vascular smooth muscle cell migration.44 One genetic variant (rs730012) in the leukotriene C4 synthase (LTC4S) gene was found to be associated with lacunar stroke in 2 different populations, with an increased risk for A-allele carriers.44 Interleukin (IL)-6 is a pleiotropic cytokine that inhibits the production of potent proinflammatory cytokines, such as tumor necrosis factor-α and IL-1.45 Increased levels of IL-6 in the plasma and cerebrospinal fluid were shown to correlate with infarct size and functional outcome of patients with stroke.45 One genetic variant (rs1800795) in the IL-6 gene was associated with lacunar stroke in 2 different populations, with an increased risk for CC-homozygotes,45,46 but it is not clear whether the samples in these 2 studies overlap, and a third study found no association.47 Two studies found an association of atherothrombotic stroke with 2 different variants in the IL-6 gene (rs1800796 and rs1800795),47,48 but these associations were not confirmed.46 None of the other associations described in single studies, between lacunar stroke and variants in CD14, IL-1β, TGFB1, and tumor necrosis factor, or between atherothrombotic stroke and variants in LTA and LTC4S, were replicated (supplemental Table II).Thrombosis and HemostasisPlatelet glycoprotein receptors are members of the integrin family, which, when activated, bind fibrinogen, von Willebrand factor, or collagen, and hence promote platelet aggregation and thrombosis.3 An increased risk of atherothrombotic stroke was found in A2-allele carriers of the integrin β-3 (ITGB3 or GPIIIa) P1(A1/A2) variant (rs5918) in 3 independent populations.49–51 However, 3 other studies did not find any association between atherothrombotic stroke and this variant,52–54 or found such an association only in subgroups of patients.52 Factor XIII catalyzes the formation of covalent bounds between fibrin monomers, which stabilizes the fibrin clot, and is also involved in the cross-linking of α-2 antiplasmin, fibronectin, and collagen.55 Two studies found an increased risk of atherothrombotic stroke associated with the Val/Val genotype of rs5985 in F13A1 (coagulation factor XIII, A1 polypeptide),55,56 but 2 other studies found no association.57,58 None of the other associations noted, between lacunar stroke and variants in F13A1, GP1BA, CPB2, and PLAT, or between atherothrombotic stroke and variants in F5, F12, FGB, ITGA, and CPB2, could be consistently replicated (supplemental Table III).Lipid MetabolismIndividuals with increased plasma cholesterol, especially low-density lipoprotein, levels are at a higher risk of premature atherosclerosis. Thus, genes encoding proteins involved in plasma lipoprotein metabolism are interesting candidates when looking for genetic risk factors of ischemic stroke. The epsilon polymorphism in exon 4 of the gene-encoding apolipoprotein E (APOE), which plays a key role in lipoprotein transport, has been extensively studied in relation with atherosclerosis and vascular events. An increased risk of atherothrombotic stroke was found for APOE ε4 carriers in 5 different studies (compared with noncarriers or to ε3 homozygotes),32,59–62 but in 1 other study the association was in the opposite direction,63 and 5 studies did not find any association.40,48,64–66 One study also observed an increased risk of atherothrombotic stroke in patients with ε2/ε2 or ε2/ε3 genotypes.62 In a meta-analysis including a portion of the data from these studies, no significant association was observed between APOE and either lacunar or atherothrombotic stroke.67 Paraoxonase 1 (PON1) prevents lipid peroxidation of low-density lipoproteins, an important early step in the atherosclerosis process. Knockout mice lacking PON1 were shown to have an increased susceptibility to atherosclerosis, and lowered PON1 activity was observed in vascular disease.68 Two studies found an increased risk of atherothrombotic stroke for carriers of the R allele or the RR genotype of rs662 in PON1,68,69 but 3 other studies did not find any association.48,70,71 The associations between lacunar stroke and variants in APOA5 or between atherothrombotic stroke and variants in ABCA1, LPA, APOA5, EPHX2, LPL, PON2, and PON3 have not been replicated (supplemental Table IV).Endothelial Function and Oxidative StressSeveral studies have suggested that mild to moderate elevations of serum homocysteine are associated with increased risk of vascular disease. Homocysteine levels tend to be higher in individuals homozygous for the thermolabile variant of the methylene tetrahydrofolate reductase (MTHFR) gene, due to a C-to-T transition at position 677. Four studies found an increased risk of atherothrombotic stroke in carriers of the TT genotype of the 677C>T variant in MTHFR,48,72–74 but 7 other studies did not find any association.32,40,72,75–78 In a meta-analysis, no association was found with the lacunar and atherothombotic stroke subtypes.79 None of the associations between lacunar stroke and variants in NOS3, MTHFR, or CYBA, or between atherothrombotic stroke and variants in NOS3 and CYBA, were consistently replicated (supplemental Table V).Genes Identified Through Linkage Analysis in an Icelandic PopulationThe DECODE group in Iceland first demonstrated linkage of stroke with the 5q12 locus using a genome-wide linkage approach80 and subsequently identified an association of stroke with genetic variants in the phosphodiesterase 4D (PDE4D) gene within this locus.81 The same group also identified significant linkage of myocardial infarction with the 13q12–13 locus, and a significant association of both myocardial infarction and stroke with variants in the arachidonate 5-lipoxygenase-activating protein (ALOX5AP) gene within this second locus.82 Several studies subsequently looked for an association of genetic variants in these 2 genes with stroke. Two studies found an increased risk of atherothrombotic stroke for carriers of the rare variant of SNP83 (rs966221) in PDE4D,81,83 but 4 other studies could not replicate this finding.84–87 None of the other associations of PDE4D and none of the associations of ALOX5AP with the lacunar and atherothrombotic stroke subtypes have been consistently replicated. In a recent meta-analysis, a borderline significant association of lacunar stroke with PDE4D SNP89 was observed (OR, 0.79 [0.62 to 1.00]; P=0.05), which became nonsignificant when the analysis was restricted to whites (Supplemental Table VI).88Other PathwaysNone of the associations of lacunar stroke with variants in CTSG, PRKCH, and mitochondrial DNA, or of atherothrombotic stroke with variants in NPY, HSPA1B, or mitochondrial DNA, have been replicated (supplemental Table VII).Other genes that have been tested, but for which no association was found in any of the published studies, are presented in supplemental Tables VIII through XII.GWASGWAS explore the genetic risk factors underlying a condition by genotyping a large number (100 000 to 1 000 000) of single nucleotide polymorphisms (SNPs) that are distributed across the chromosomes; they assume no a priori hypothesis regarding genomic loci of interest. They have been applied to a number of complex diseases with several notable successes, eg, the identification of previously unsuspected genes conferring an increased risk of diabetes31 and coronary heart disease.89 So far, only 1 GWAS has been published on ischemic stroke.90 This study compared 408 803 SNPs in 249 white patients with ischemic stroke and 268 white controls, using the Illumina Infinium Human-1 and HumanHap300 SNP chips (Illumina Inc, San Diego, Calif). None of the polymorphisms reached the threshold for genome-wide significance, for ischemic stroke overall and for all ischemic stroke subtypes. However, the statistical power of this pilot study was insufficient to detect small size effects (OR <1.5), especially for rarer genetic variants.90 Noteworthy, in the genome-wide analysis for large- and small-artery ischemic stroke, none of the SNPs with the lowest probability values (<10−4) was located in any of the previously reported candidate genes.90Linkage StudiesLinkage studies are family based and test whether genetic markers cosegregate with a given disease within families. They have been used successfully to identify genes underlying monogenic forms of ischemic stroke, such as cerebral autosomal dominant arteriopathy, subcortical infarcts and leukoencephalopathy,9 but they are less powerful when the pattern of inheritance is not mendelian,91 which is true for most ischemic strokes.Two genome-wide linkage studies on sporadic ischemic stroke have been published.80,92 The first study used a multipoint, affected-only allele-sharing method in 476 patients with stroke and 438 of their relatives, and found strong evidence for linkage with a logarithm of odds score of 4.86 on chromosome 5q12 for ischemic stroke.80 When ischemic stroke subtypes were investigated, the logarithm of odds scores were still positive but smaller than those observed in the overall analysis, consistent with a loss of power because of the smaller sample sizes (detailed results were not published). The second study did not identify any new stroke locus and did not report linkage analyses for ischemic stroke subtypes.92 Other studies that attempted to replicate the genetic linkage with the chromosome 5 locus did not report results on ischemic stroke subtypes.83,93DiscussionAlthough they represent only a limited proportion of the published genetic association studies on ischemic stroke, a substantial number of studies have looked for genetic risk factors underlying lacunar and atherothrombotic stroke. Most of these studies were negative. Several significant associations that were described were not replicated in independent populations. Only a very small number of associations were found in at least 2 independent samples: these are associations of lacunar stroke with ACE32–34 and LTC4S45,46 variants, and of atherothrombotic stroke with ITGB3,49–51F13A1,55,56APOE,32,59–63PON1,68,69MTHFR,48,72,73 and PDE4D81,83 variants. For most of these associations, there are also negative studies that were published, so that even these remain controversial. Interestingly, in most instances genetic associations differed between lacunar and atherothrombotic stroke, which supports the notion that their genetic backgrounds are distinct.LimitationsPublished studies on the genetic risk factors for sporadic atherothrombotic and lacunar stroke suffer from limitations that are similar to those of most genetic association studies on stroke,94 and most candidate gene association studies in general.30,94 The 2 main limitations are (1) the lack of replication in independent samples of the vast majority of positive associations and (2) the insufficient statistical power of most studies to detect modest associations.30,94 The sample sizes needed to achieve a statistical power ≥80% (assuming an additive genetic model, and a type I error rate <0.05) can be estimated at 267 cases, and the same number of controls for a SNP with a minor (rare) allele frequency of 20% and an OR≥1.5 (http://pngu.mgh.harvard.edu/∼purcell/gpc/). This number increases to 385 and 646 for ORs of 1.3 and 1.1, respectively. If the minor allele frequency is 10%, the numbers become 455, 843, and 2372. Among the studies reviewed here, most had <100 subjects per group.Other limitations are more specific to the study of stroke subtypes. Most studies tested the association of genetic variants with several ischemic stroke subtypes in a secondary analysis, and only a few of them adjusted for multiple testing, thus leading potentially to spurious associations. Moreover, the variation in the criteria used to define ischemic stroke subtypes may lead to substantial heterogeneity in the phenotype definition.95 This may have either diluted real effects of genetic variants or may lead to nonspecific associations, and thus could explain contradictory findings between studies. Some studies used mechanistic subtyping systems (such as the Classification of Cerebrovascular Diseases III,96 International Classification of Diseases, or Trial of Org 10172 in Acute Stroke Treatment1 system), which classify stroke on the basis of inferred origin of cerebrovascular occlusion.95 Other studies used systems based on clinical presentation or location and size of the lesion within the brain (such as the Oxfordshire Community Stroke Project system97) that are practical, but may result in less homogenous categorization of stroke subtypes from a mechanistic point of view.In this review, we have not addressed the genetic variation in copy number, telomeric length, or epigenetic mechanisms as possible explanations for the observed heritability of stroke risk. Finally, although efforts were made to be comprehensive in the retrieval of studies, it is possible that relevant studies were inadvertently missed.Future DirectionsThere is an urgent need for large genetic association studies designed specifically to look for genetic risk factors underlying ischemic stroke subtypes. The atherothrombotic and lacunar subtypes are particularly important because they are the most frequent causes of ischemic stroke and because there is some evidence that they have a stronger genetic component than other ischemic stroke subtypes.5–7 The genotyping of large numbers of well-phenotyped patients, defined according to standardized and validated mechanistic classification systems, will require large collaborative efforts, such as the International Stroke Genetics Consortium (www.strokegenetics.org), the Cohorts for Heart and Aging Research in Genetic Epidemiology consortium, or the Candidate Gene Association Resource.98Genetic marker selection can be improved by studying several SNPs and haplotypes instead of single markers on a given gene to account for possible allelic variation between individuals and ethnic groups and by simultaneously studying several genes in the same pathway instead of a single gene, with adequate correction for multiple testing. GWAS offer a promising alternative, permitting an unbiased approach, without any a priori assumptions regarding the underlying pathophysiology. Preplanned replication of positive findings is highly recommended. Emerging statistical and bioinformatic techniques that improve our ability to study gene-gene and gene-environment interactions may assist in uncovering novel genetic variation underlying stroke risk.Genetic association studies on intermediate phenotypes of atherothrombotic and lacunar stroke, such as carotid intima-media thickness and plaques, or white matter hyperintensities on brain MRI, could also help identify genetic susceptibility factors to these stroke subtypes. Indeed, these intermediate traits are highly heritable, quantitative, and can be assessed noninvasively in large population samples, thus increasing" @default.
• W2104967400 created "2016-06-24" @default.
• W2104967400 creator A5011863508 @default.
• W2104967400 creator A5077569991 @default.
• W2104967400 date "2009-04-01" @default.
• W2104967400 modified "2023-09-26" @default.
• W2104967400 title "Genetics of Atherothrombotic and Lacunar Stroke" @default.
• W2104967400 cites W1518778416 @default.
• W2104967400 cites W153053541 @default.
• W2104967400 cites W1562398856 @default.
• W2104967400 cites W1948965777 @default.
• W2104967400 cites W1971362781 @default.
• W2104967400 cites W1971633615 @default.
• W2104967400 cites W1971808641 @default.
• W2104967400 cites W1978215768 @default.
• W2104967400 cites W1986828651 @default.
• W2104967400 cites W1990165810 @default.
• W2104967400 cites W1993719373 @default.
• W2104967400 cites W1994272289 @default.
• W2104967400 cites W1995301558 @default.
• W2104967400 cites W2007599203 @default.
• W2104967400 cites W2007624510 @default.
• W2104967400 cites W2011455194 @default.
• W2104967400 cites W2014955376 @default.
• W2104967400 cites W2021556801 @default.
• W2104967400 cites W2021691830 @default.
• W2104967400 cites W2022356406 @default.
• W2104967400 cites W2025235506 @default.
• W2104967400 cites W2030092286 @default.
• W2104967400 cites W2030402387 @default.
• W2104967400 cites W2031469444 @default.
• W2104967400 cites W2035292932 @default.
• W2104967400 cites W2035914863 @default.
• W2104967400 cites W2038618373 @default.
• W2104967400 cites W2042103448 @default.
• W2104967400 cites W2043362204 @default.
• W2104967400 cites W2044472697 @default.
• W2104967400 cites W2046020898 @default.
• W2104967400 cites W2050010609 @default.
• W2104967400 cites W2051453521 @default.
• W2104967400 cites W2055851746 @default.
• W2104967400 cites W2069232156 @default.
• W2104967400 cites W2072244849 @default.
• W2104967400 cites W2072372077 @default.
• W2104967400 cites W2078103827 @default.
• W2104967400 cites W2079811458 @default.
• W2104967400 cites W2080669135 @default.
• W2104967400 cites W2083920293 @default.
• W2104967400 cites W2084110368 @default.
• W2104967400 cites W2087125448 @default.
• W2104967400 cites W2092074084 @default.
• W2104967400 cites W2097085094 @default.
• W2104967400 cites W2098735045 @default.
• W2104967400 cites W2100140681 @default.
• W2104967400 cites W2100720749 @default.
• W2104967400 cites W2103795629 @default.
• W2104967400 cites W2106210259 @default.
• W2104967400 cites W2107901484 @default.
• W2104967400 cites W2113594477 @default.
• W2104967400 cites W2114904765 @default.
• W2104967400 cites W2114945231 @default.
• W2104967400 cites W2118900930 @default.
• W2104967400 cites W2119287668 @default.
• W2104967400 cites W2120451046 @default.
• W2104967400 cites W2121756636 @default.
• W2104967400 cites W2126180842 @default.
• W2104967400 cites W2126973086 @default.
• W2104967400 cites W2129148616 @default.
• W2104967400 cites W2129932769 @default.
• W2104967400 cites W2130580941 @default.
• W2104967400 cites W2138595885 @default.
• W2104967400 cites W2139110550 @default.
• W2104967400 cites W2139514338 @default.
• W2104967400 cites W2147431297 @default.
• W2104967400 cites W2147758955 @default.
• W2104967400 cites W2154730509 @default.
• W2104967400 cites W2154775290 @default.
• W2104967400 cites W2156263958 @default.
• W2104967400 cites W2157456501 @default.
• W2104967400 cites W2160462328 @default.
• W2104967400 cites W2164447582 @default.
• W2104967400 cites W2169167682 @default.
• W2104967400 cites W2323783182 @default.
• W2104967400 cites W2914437448 @default.
• W2104967400 cites W697503 @default.
• W2104967400 doi "https://doi.org/10.1161/circgenetics.108.828319" @default.
• W2104967400 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2798146" @default.
• W2104967400 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20031584" @default.
• W2104967400 hasPublicationYear "2009" @default.
• W2104967400 type Work @default.
• W2104967400 sameAs 2104967400 @default.
• W2104967400 citedByCount "9" @default.
• W2104967400 countsByYear W21049674002012 @default.
• W2104967400 countsByYear W21049674002013 @default.
• W2104967400 countsByYear W21049674002015 @default.
• W2104967400 countsByYear W21049674002016 @default.
• W2104967400 countsByYear W21049674002021 @default.
• W2104967400 countsByYear W21049674002022 @default.

• next